Abstract: A vehicle includes a component coated with a pollutant reduction catalyst configured to remove pollutants from a flow of air over the component, a catalyst temperature sensor coupled to the component, a general temperature sensor, a vehicle speed sensor, and an active grille shutter (AGS) system having a plurality of movable grille shutters. A controller is configured to determine an efficiency of the pollutant reduction catalyst based on signals from the catalyst temperature sensor, the general temperature sensor, the vehicle speed sensor, and the AGS system.

Abstract: A cleaning and piston replacement kit for an accumulator of a vehicle transmission which includes a brush for cleaning, reconditioning and polishing worn accumulator bores and replacement pistons each of which includes a pair of sealing rings for supporting and spacing the replacement pistons from the accumulator bores to thereby prevent scrapping of the walls of the bores by movement of the pistons within the bores and a method of reconditioning the accumulator bore.

Abstract: Recombinant materials for the production of low molecular weight hydrophobic lung surfactant proteins are disclosed and claimed. The monomeric forms of the proteins from human and canine sources have apparent molecular weights of about 5 kd and form dimers under some conditions. The availability of these recombinant materials permits production of large amounts of these proteins through recombinant techniques and permits the use of these proteins in pharmaceutical compositions in the treatment of respiratory deficiency syndromes.

Abstract: The complete coding sequences and amino acid sequences for both canine and human 32K alveolar surfactant proteins (ASP) are disclosed; clones encoding variants of the SP-18 and SP-5 forms of human protein are disclosed. Methods and vectors for obtaining these proteins in recombinant form are also described. An improved method for purification of the 32K protein takes advantage of its carbohydrate affinity. Pharmaceutical compositions in the treatment of respiratory deficiency syndrome use the 10K proteins with or without the 32K form. Synthetic peptides based on the human SP-5 protein are provided as well, which peptides show significant ASP activity.

Abstract: Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques.

Abstract: Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques.

Abstract: Various specific human SP-18 and human SP-5 derived peptides have alveolar surfactant protein (ASP) activity. These peptides are prepared using synthetic methods or by recombinant techniques. The peptides of the invention include surfactant proteins having serine replacements for the cysteines.

Abstract: A method and apparatus for draw forming a metal sheet over a male form to produce a three-dimensional shape. A sheet of metal is clamped between upper and lower draw plates positioned above the male form. The upper plate has an edge conforming to the male form shape. The plates and sheet are moved downwardly over the form with the edge of the upper plate firmly pressing the sheet against the form. The clamping pressure between the draw plates allows suitable slippage as drawing proceeds to produce a drawn shape of intended thickness. The drawn shape has a configuration conforming to the outer surface of the male form and has an outer surface of improved uniformity and appearance due to the wiping action of the upper plate edge.

Abstract: The complete coding sequences and amino acid sequences for both canine and human 32K alveolar surfactant proteins (ASP) are disclosed; clones for the 10K protein have also been obtained. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.

Abstract: The complete coding sequences and amino acid sequences for both canine and human 32K alveolar surfactant proteins (ASP) are disclosed; clones for the 10K protein have also been obtained. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.

Abstract: The complete coding sequences and amino acid sequences for both canine and human alveolar surfactant protein (ASP) are disclosed. Methods and vectors for obtaining these proteins in recombinant form are described. The availability of large amounts of these proteins through recombinant techniques permits the use of ASP in suitable pharmaceutical compositions in the treatment of respiratory deficiency syndromes.